References
- Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
- Saiman L, Siegel J, LiPuma J, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35:S1-S67
- Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013;22:205-16
- Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-9
- Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-13
- Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61
- Knudson RJ, Lebowitz MD, Holberg CJ, et al. Changes in the normal maximal expiratory flow–volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34
- Council For Clinical Certification in Audiology and Speech-Language Pathology of the American Speech-Language-Hearing Association. Standards for the Certificate of Clinical Competence in Audiology, 2012. Available at: http://www.asha.org/Certification/2012-Audiology-Certification-Standards/[Last accessed 30 September 2014]
- Konstan MW. Long-term safety and efficacy of tobramycin inhalation powder in cystic fibrosis patients with P. aeruginosa: the edit trial and its two open-label extension studies. 27th North American Cystic Fibrosis Conference 2013, Salt Lake City, UT, USA, 2013
- Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014;13:692-8
- Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8
- Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-34
- Thompson V, Kloster M, Flume PA, et al. Hemoptysis is associated with underlying disease severity and is an expected adverse event in cystic fibrosis clinical trials. Pediatr Pulmonol 2014;49:352-3
- Galeva I, Konstan MW, Higgins M, et al. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr Med Res Opin 2013;29:947-56
- Liou TG, Elkin EP, Pasta DJ, et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010;9:250-6